NICE releases Medtech Innovation Briefing on calprotectin point of care and home testing for monitoring IBD treatment

On 4th December 2017 the National Institute for Health and Care Excellence issued a Medtech Innovation Briefing [MIB132]: ‘Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease’.

This describes the innovative aspect that test results can be acted on more quickly than waiting for standard laboratory tests and could help reduce colonoscopies and clinical appointments. Costs may also be saved if the tests can more quickly identify ineffective treatments. Implementing the technologies may need changes to the NHS care pathway.

The brief covers five faecal calprotectin assays including BÜHLMANN IBDoc® home test and Quantum Blue® fCAL Point of Care test